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HumanThe possible beneﬁcial effects of coenzyme Q10 (CoQ10) supplementation on disease progression and oxidant
status in diabetes remains debated. In the present study, patients with type 1 and type 2 diabetes were treated
with oral CoQ10, 100mg twice daily for 12weeks.We assessed total antioxidant capacity, intra- and extracellular
levels of the redox regulating protein glutaredoxin 1 (Grx1), CoQ10, oxidized LDL-cholesterol, lipid proﬁle and
HbA1c.We have previously shown that extracellular Grx1 is increased in patientswith type 2 diabetes compared
to healthy subjects. In the present study, CoQ10 treatment signiﬁcantly decreased serum Grx1 activity as well as
total antioxidant capacity independent of type of diabetes, indicating an improvement to a less oxidized extracel-
lular environment. The effect on serum Grx1 activity was more prominent in patients not on statin treatment.
Conversely, intracellular Grx1 activity as well as mRNA levels increased independent of statin treatment. There
was a signiﬁcant improvement in oxidized LDL-cholesterol and lipid proﬁle, with a tendency to improved meta-
bolic control (HbA1c). Additionally, we describe for the ﬁrst time that CoQ10 is a direct substrate for glutathione,
and that Grx1 catalyzes this reaction, thus presenting a novel mechanism for CoQ10 reduction which could ex-
plain our ﬁndings of an increased intracellular Grx1. In conclusion, 12 weeks CoQ10 treatment signiﬁcantly im-
proved the extracellular redox balance and lipid proﬁle, indicating that prolonged treatmentmay have beneﬁcial
effects also on clinical outcome in diabetes.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Glutaredoxins (Grxs) are redox proteins that catalyze glutathione
(GSH) dependent thiol disulﬁde oxidation reduction reactions in the
cytosol or mitochondria [1,2]. Grx is oxidized by substrate proteins,
and subsequently reduced by GSH. Grx also uniquely catalyzes the
deglutathionylation ofmixed disulﬁdes of proteinswith GSH, and by re-
versible glutathionylation regulates the activity of several proteins,
among them apoptosis regulating proteins, e.g. ASK-1 and NFκβ that
are found to be dysregulated in diabetes [2]. Patients with diabetesellitus;Grx1, glutaredoxin1;GR,
e constant; NADP, nicotinamide
clear cell; TAC, total antioxidant
edicine and Surgery, Karolinska
. This is an open access article under(DM) have an oxidized intracellular environment compared to healthy
subjects as hyperglycemia impairs the redox balance and produces
ROS [3,4], which triggers diabetes complications, and DM related mor-
bidity andmortality [5–7].We have previously shown that Grx1 plasma
activity is increased in type 2 DM compared to healthy subjects, sug-
gesting that extracellular Grx1 activity is a marker of oxidative stress.
Additionally, non-diabetic patients had an impaired Grx1 secretion
upon excessive glucose stimulation [8]. Thus, serum Grx1 activity may
be a prognostic marker in the development of type 2 DM and possibly
a marker of DM related oxidative stress which may lead to organ dam-
age. Recent studies have shown that upregulation of Grx1 attenuates re-
vascularization after arterial ischemia [9], implying the importance of
low Grx1 levels especially in DM patients who have an increased risk
of developing atherosclerosis, and that long term CoQ10 treatment im-
proves morbidity in chronic heart failure.
CoQ10 is a lipid soluble endogenous antioxidant, existing in an oxi-
dized (ubiquinone) and reduced (ubiquinol) form, and a radical inter-
mediate semiquinone. CoQ10 is essential for the mitochondrialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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is present in all membranes including the plasmamembrane as an anti-
oxidant by inhibiting initiation and propagation of lipid and protein ox-
idation and regenerating ascorbate and tocopherol [10,11]. Serum levels
of CoQ10 have been reported to be either high or low in type 2 DM com-
pared to healthy subjects [3,12,13], where higher levels in DM than in
healthy subjects are interpreted to indicate a respons to increased ROS
production. Lower levels in DM compared to healthy subjects is report-
ed to be due to deﬁcient production [3,12,13]. Preclinical data shows
that CoQ10 protects endothelial cells from glucose induced oxidative
stress [14], and a number of recent studies in diabetic mice show that
CoQ10 protects the mice from developing diabetic nephropaty [15],
neuropathy [16,17], and cardiomyopathy [18]. Additionally CoQ10 pro-
tects from β amyloid uptake in a model of Alzheimer's disease [19].
CoQ10 is thus important for neuromuscular function, kidney- and
heart function. Several clinical studies have been conducted with
CoQ10 supplementation in DM, some showing beneﬁcial effects on clin-
ical parameters [20–22], while others have not. Recently, a randomized
controlled trial of heart failure patients, of whom 10% had diabetes
treated with standard therapy or standard therapy with CoQ10 for
two years, found that CoQ10 (ubiquinone) treatment reduced the over-
all cardiovascular-mortality and improved heart function [23]. Similarly,
a prospective randomized double blind, placebo controlled trial with
CoQ10 and selenium in combination, showed a reduction in long term
cardiovascular mortality in a large study of elderly people, of whom
20% had diabetes [24].
In the present study we investigate the possible beneﬁcial effect of
dietary supplementation with CoQ10, at 100 mg twice daily, in a popu-
lation of type 1 and type 2 diabetic patients. The studywas not powered
by sample size or follow-up time to assess clinical parameters or out-
come. The aims were to assess the intracellular and extracellular levels
of the oxidative stress parameter Grx1, and to investigate possible inter-
actions between CoQ10 and Grx1.
2. Material and methods
TrxR1 enzyme, hGrx1 and ﬂuorescent Grx1 activity kit were from
IMCO (IMCO Corporation Ltd; www.imcocorp.se), CoQ10 (ubiquinone)
was a gift from PharmaNord (Vejle, Denmark), NADPH and all other re-
agents were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).
2.1. Patients
22 patients, diagnosed with type 1 or type 2 DM according to WHO
guidelines [25], were enrolled in the study at the Department of
Endocrinology, Metabolism and Diabetes, Karolinska University Hospi-
tal, Stockholm, Sweden, after giving informed written and oral consent.
The study was approved by the regional Ethics Committee in
Stockholm, and was carried out in accordance with the Declaration of
Helsinki.
2.2. CoQ10 administration and sample collection
After overnight fasting, venous blood was drawn from the
antecubital vein, at study enrollment and after 12 weeks of oral CoQ10
(ubiquinone) treatment. All patients received 100 mg CoQ10 supple-
mentation twice daily for 12 weeks. Heparin tubes were collected and
PBMC separated using a Ficoll gradient centrifugation, and PBMC quick-
ly frozen at −20 °C until analysis. Heparin tubes were centrifuged
20 min at 2500 ×g, where after plasma was collected quickly frozen
and kept at−80 °C until further analysis.
2.3. Routine laboratory investigations
The lipid proﬁle and glycemic status were determined according
to standard procedures at the Karolinska University Hospital ClinicalLaboratory (www.diagnosticsample.com), using the automated DXC
Beckman-Coulter instrument (www.beckmancoulter.com). HbA1c was
determined using the MonoS method, Unimate (Roche Diagnostics,
Basel, Switzerland). To convert HbA1cMonoS into HbA1cNGSP, the for-
mula NGSP = 0.92 ∗MonoS + 1.33 is used.
2.4. Determination of oxidized LDL
The plasma concentration of oxidized LDL was determined by com-
mercially available sandwich ELISA according to the manufacturer's de-
scription (Mercodia AB, Uppsala, Sweden).
2.5. CoQ10 detection
CoQ10 was extracted from the samples according to Bentinger et al.
[26] with some modiﬁcations. 200 μL serum and 300 μL water were
mixed, 5 mL methanol was added and the sample was vortex-mixed
for 1 min, 1.2 mL petroleum-ether was added and shaken by hand for
about 15 s. Finally, phase separationwas obtained by adding2mLmeth-
anol and 1.8mL petroleum-ether andwhere after the sample was shak-
en again for 15 s, where after the samples were centrifuged, and the
upper phase was transferred to a new tube and evaporated under
nitrogen.
Samples were dissolved in chloroform:methanol 2:1 and a por-
tion injected for reversed phase separation on HPLC using a C18 col-
umn (150 × 3.9 mm, 5 μm particle size, Waters Millipore, MA)
equipped with a Supelco C8 pre-column (50 × 3.9 mm, 5 μm,Waters
Millipore). A linear gradient was used from methanol:water 9:1 to
methanol:isopropanol:hexane 2:1:1 for 25 min with UV-detection at
210 and 275 nm. Peaks were identiﬁed with corresponding standards.
2.6. Grx1 activity assay in serum and PBMC
Grx1 activity in serumor PBMCwas determinedwith a commercial-
ly available Fluorescent Grx1 activity assay kit (IMCO Corporation Ltd;
www.imcocorp.se) developed in our group [8]. In brief, 20 μL of serum
or 40 μL PBMC lysate was mixed thoroughly with 70 μL of 100 mM po-
tassium phosphate buffer, pH 7.5, containing 1 mM EDTA, 0.5 mMGSH,
0.25 mMNADPH, 50 nM baker yeast and glutathione reductase (GR) in
a 96-well plate. Then 10 μL of ﬂuorescent albumin (BSA-S-SG-E) was
then added to each well to initiate the reaction. A reaction solution con-
taining plasma/PBMC lysate but not GSH, NADPH, or GR was used as
background. The emission at 540 nmwas recorded after 520 nm excita-
tion using a VICTOR3 Multilabel Plate Reader (PerkinElmer, USA). Grx1
activity was determined by measuring the initial reaction velocity
from a linear ﬂuorescence increase. Varied concentrations of recombi-
nant hGrx1 (IMCO Corporation Ltd AB, Stockholm, Sweden) were
used to obtain a standard curve, based on which the corresponding
Grx activity was calculated. We approximate that essentially all serum
Grx activity consists of Grx1 activity, as previously described [27].
2.7. Glutathione-dependent CoQ10 reduction catalyzed by Grx1
In vitro experiments of ubiquinonewere carried out by adding up to
75 μM CoQ10 to a reaction mixture containing 10 mM GSH, 10 nM GR
and 0.2 mM NADPH recording the NADPH oxidation spectrophotomet-
rically at 340 nm. To study the catalyzed reaction, 20 μM Grx1 was
added to the reaction mixture.
2.8. Thioredoxin reductase (TrxR1) catalyzed GSH-dependent CoQ10
reduction
To compare the previously described CoQ10 reduction catalyzed by
TrxR [28] to that of GSH and Grx1, and to determine the reaction rate
under our experimental setup, up to 100 μM CoQ10 was added to a re-
action mixture containing a ﬁnal concentration of 100 nM TrxR1 and
Table 1
Patient characteristics at baseline. The type 1 and type 2 DM patients had similar baseline characteristics, regarding age, gender, clinical parameters and biochemical parameters, except
for diabetes duration, lipid proﬁle, and BMI. There was a signiﬁcantly higher use of statin treatment and in type 2 diabetes patients. No signiﬁcant differences were observed in baseline
CoQ10 levels, intracellular or extracellular Grx levels between type 1 and type 2 DM patients. Reference levels for healthy population are HbA1c% b5.1%, fp-TG 0.45–2.6 mmol/L, fp-HDL
1.0–2.7mmol/L, fp-LDL cholesterol 2.0–5.3mmol/L, and total cholesterol b5mmol/L. For Grx, we previously reported serumGrx levels of 15.2 ng/mL in healthy individuals (8). There is no
established reference range for oxidized LDL or PBMC Grx.
Type 1 diabetes Type 2 diabetes p-Value
Age (median, range) 57 (35–71) 63 (52–70) ns
Gender (m/f) 6/7 6/3
Statin (yes/no) 4/9 7/2 p b 0.05
Years of disease (median, range) 31 (8–53) 8(3–38) p b 0.05
HbA1c % MonoS (median, range) 6.7 (4.5–9.0) 6.4 (5.0–8.4) ns
BMI (median, range) 23.4 (21.6–35.6) 28.6 (23.7–41) p = 0.004
Blood pressure (median, range) 128/80 (110–144/65–93) 125/80 (120–140/60–98) ns
fp-TG, mmol/L (median, range) 0.64 (0.4–2.5) 1.3 (0.87–2.0) p b 0.05
fp-HDL, mmol/L (median, range) 1.8 (0.8–2.5) 1.0 (0.7–2.0) p b 0.01
fp-LDL cholesterol, mmol/L (median, range) 2.3 (1.9–4.3) 2.6 (1.6–2.9) ns
Serum CoQ10, nmol/L(median, range) 1.70 (1.1–3.3) 1.75 (1.0–3.4) ns
Total cholesterol, mmol/L(median, range) 4.9 (3.6–6.2) 4.4 (3.1–5.4) ns
CoQ10/cholesterol (median, range) 0.35 (0.20–0.92) 0.48 (0.29–0.77) ns
Oxidized LDL cholesterol (nM) 37.3 (24.5–63.3) 48.6 (22.2–75.5) ns
Serum Grx (ng/mL) 52.9 (27.2–69) 57.7 (29.8–68) ns
PBMC Grx (ng/μg) 0.5 (0.32–0.87) 0.6 (0.30–0.80) ns
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spectrophotometer at 340 nm for 30 min.
2.9. Total antioxidant capacity (TAC) assay
TAC was measured with a spectrophotometer in 96-well plates,
using the Antioxidant Assay Kit (Sigma) as per the manufacturer's in-
structions. After 5 min incubation, reaction was stopped and the end-
point absorbance at 405 nm was determined using a microplate
reader (SpectraMax 340PC, 384 — Molecular Devices). All samples
were performed in duplicate. A reference curve based on the soluble
antioxidant Trolox was used, and TAC was expressed in Trolox
concentration (mM).
2.10. RNA extraction and quantitative PCR
Total RNA was isolated and cDNA was reversely transcribed
using Omniscript Reverse Transcription Kit protocol (Qiagen, Hilden,Table 2
Effects of 12 weeks of CoQ10 treatment on CoQ10, Grx, HbA1c and lipids in 22 patients with D
together.Median, range are given and signiﬁcance at the level of p b 0.05 (*), or b0.01 (**). Upon
p-cholesterol, as well as oxidized LDL-cholesterol, with more pronounced changes in the non-
population, and interestingly a signiﬁcant increase in the statin treated groupwhere in fact all 1
CoQ10 increased.
Non-statin treated Statin
0 w 12 w 0 w
S-CoQ10 (mmol/L) 1.8 (1.1–3.4) 5.1 (4.1–7.3)⁎⁎ 1.5 (
S-Grx (ng/mL) 52.9 (27–69) 30.2 (26–45)⁎⁎ 54.7 (
Grx PBMC (ng/μg prot) 0.5 (0.32–0.87) 0.7 (0.44–0.99) 0.5 (
HbA1ca (%) 6.7 (5.4–9.0) 6.5 (5.5–8.3) 6.0 (
p-HDL (mmol/L) 1.4 (0.9–2.5) 1.4 (1.9–2.4) 1.0 (
p-LDL (mmol/L) 2.5 (2.0–4.3) 2.2 (1.7–3.2)⁎ 2.3 (
p-Triglycerides (mmol/L) 0.7 (0.4–2.5) 0.7 (0.4–1.5) 1.3 (
Ox. LDL 38.2 (24–63) 34.2 (22–47)⁎⁎ 38.3 (
p-Total cholesterol 4.9 (3.6–6.2) 4.3 (3.9–5.2)⁎⁎ 4.4 (
CoQ10/cholesterol 0.35 (0.22–0.92) 1.15 (0.84–1.8)⁎⁎ 0.42(
Reference levels for healthy population are HbA1c% b5.1%, fp-TG 0.45–2.6 mmol/L, fp-HDL 1.0
viously reported serum Grx levels of 15.2 ng/mL in healthy individuals (8). There is no establis
a HbA1c measured with the MonoS method.
⁎ p b 0.05 for 12 w vs. 0 w.
⁎⁎ p b 0.01 for 12 w vs. 0 w.Germany) according to the manufacturer's instructions, followed by
quantitative PCR (qPCR) for Grx1 (primer sequences forward: TGCAAA
ATCCAGCCTGGGAAG, reverse: TTGAATCTCGTTAGTGTGGTTGGT. β-Actin
was used as a housekeeping gene. qPCR was carried out using SYBR
Green qPCR Super Mix (Invitrogen, Carlsbad, CA, USA) in Bio-Rad iCycler
(Bio-Rad, Hercules, CA). The expression ratio was calculated using the
ΔΔCT method. cDNA, SYBR Green PCR Master Mix (Invitrogen, Carlsbad,
CA, USA), and forward and reverse primers at 300 nM concentration
were added to each well. Speciﬁcity of the PCR reaction was validated
by melting curve analysis. All qPCRs were performed in duplicates.2.11. Statistical analyses
The Wilcoxon matched pair test was used to compare 0 weeks and
12 weeks, assuming non-Gaussian distribution of samples. The differ-
ence between groups was compared with Mann–Whitey U test. Differ-
ences were considered to be signiﬁcant if p b 0.05.M, analyzed in non-statin treated (n = 11) and statin treated (n= 11) separately, and all
CoQ10 treatment, therewas a signiﬁcant reduction in serumGrx, fp-LDL-cholesterol, total
statin treated group. There was a tendency to reduced HbA1c levels in the whole patient
1 patients individually lowered HbA1c. Intracellular Grx increased signiﬁcantly, and serum
treated All patients
12 w 0 w 12 w
1.0–2.8) 4.0 (3.4–9.0)⁎⁎ 1.7(1.0–3.4) 5.0(3.4–9.0)⁎⁎
29–68) 43.6 (25–67) 54 (27–69) 38 (25–67)⁎
0.3–0.84) 0.7 (0.44–0.99) 0.5 (0.3–0.9) 0.7 (0.4–1.3)⁎
4.5–8.4) 5.7 (4.3–7.6)⁎ 6.5 (4.5–9) 5.9 (4.3–8.3)
0.8–2.3) 1.0 (0.8–1.8 1.2 (0.7–2.5) 1.3 (0.7–2.4)
1.6–3.9) 2.1 (1.6–3.4) 2.4 (1.6–4.3) 2.2 (1.4–3.4)⁎
0.5–2.0) 1.3 (0.6–2.0) 1.0 (0.4–2.5) 1.0 (0.4–2)
22.-75) 36.7 (29–49)⁎ 38.2 (22–75) 35.9 (22–49)⁎⁎
2.9–5.4) 3.9 (2.7–5.8) 4.6 (3.1–6.2) 4.0 (2.5–5.8)⁎
0.29–0.63) 1.25 (0.76–2.6)⁎⁎ 0.45 (0.22–0.92) 1.24 (0.76–2.6)⁎
–2.7 mmol/L, fp-LDL 2.0–5.3 mmol/L, and total p-cholesterol b5 mmol/L. For Grx, we pre-
hed reference range for oxidized LDL or PBMC Grx.
Fig. 1. Serum Grx1 activity in 22 diabetes patients before and after 12 weeks of CoQ10
treatment. Mean and SD are shown. Serum Grx1 activity signiﬁcantly decreased upon
CoQ10 treatment in the whole patient cohort (a). The decrease was signiﬁcant in non-
statin treatedpatients (p b 0.05) but not signiﬁcant in the statin treated cohort (b). The de-
crease in Grx1 activity was similar regardless of the type of DM (c), however two of the
four type 1 DM patients on statin treatment had no decrease in Grx in response to
CoQ10 (statin treated type 1 DM patients marked with red arrow).
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3.1. Patient characteristics and effect of CoQ10 on clinical parameters
Of the 22 patients enrolled in the study, 13 had type 1 DMand 9 had
type 2 DM. Patient characteristics are described in Table 1, reference
levels given in the table legend. Statin use was more frequent in the
type 2 DM group (67% of type 2 DM patients were on statin treatment
compared to 31% of type 1 DM patients), and the baseline lipid proﬁle
was signiﬁcantly dysregulated in the type 2 DM group. Baseline serum
CoQ10 levels were similar between the groups, and higher than found
in healthy individuals [8]. Serum CoQ10 levels increased signiﬁcantly
upon treatment, with no difference between statin treated or non-statin
treated patients (Table 2).
Subgroup analysis of the 11 statin treated and 11 non-statin treated
patients showed that even though there were no signiﬁcant differences
at baseline lipid status between statin treated andnon-statin treated pa-
tients, p-LDL, oxidized LDL, and total p-cholesterol decreased signiﬁ-
cantly only in the non-statin treated group. However, the CoQ10/
cholesterol ratio decreased signiﬁcantly in both subgroups, and HbA1c
decreased signiﬁcantly only in the statin treated group, where actually
all patients individually decreased their HbA1c (Table 2).3.2. Serum Grx1 activity and total antioxidant capacity
SerumGrx1 activity decreased signiﬁcantly after 12 weeks of CoQ10
treatment, from a median of 54 ng/mL (range 27–69) to 38 ng/mL
(range 25–68), p b 0.05 (Fig. 1a and Table 2). Patients were further
subdivided according to the statin treatment or not (Fig. 1b), and type
of DM (Fig. 1c), to assess in which patient subgroup the decrease in
Grx1 activity was most prominent. The results clearly show a marked
reduction in extracellular Grx1 activity in non-statin treated patients,
however not in statin treated patients (Table 2, Fig. 1b). Since only 4
of 13 type 1 DM patients were on statin treatment compared to 7 of 9
type 2 DM patients, it is difﬁcult to assess the importance of DM type
on Grx1 levels, however it is worth noting that two of the four DM
type 1 patients on statin treatment did not decrease their Grx1 levels
at all (Fig. 1c).
To conﬁrm the above result, total antioxidant capacity (TAC) was
measured if remaining sample amount allowed (n = 8 of which four
type 1 DM, four type 2 DM; four of these patients were on statin treat-
ment). Similar to the decrease in plasma Grx1 activity and oxidized
LDL cholesterol, there was a signiﬁcant decrease in plasma TAC
(p b 0.05), Fig. 2.Fig. 2. Serum total antioxidant capacity (TAC) was measured in eight representative pa-
tients. Of these, four had type 1 DM and four had type 2 DM, and four of the eight patients
were on statin treatment. As seen for serumGrx1 activity, therewas a signiﬁcant decrease
in TAC after 12 weeks of CoQ10 treatment (p b 0.05).
Fig. 5. Amount of CoQ10 reduced, with either 10 mM GSH, 0.2 mM NADPH and varying
CoQ10 concentration, with and without 20 μM Grx1, or 0.1 μM TrxR, 0.2 mM NADPH
with 50 μM CoQ10. We assume that 1 mol oxidized NADP+ equals 1 mol reduced
CoQ10. GSH is a better reductant than TrxR, and the reaction is catalyzed by the addition
of Grx1.
Fig. 4. PBMCmRNA expression of Grx1 increased signiﬁcantly (p b 0.05) upon 12weeks of
CoQ10 treatment, n = 22.
Fig. 3. Intracellular PBMCGrx activity before and after 12weeks of CoQ10 treatment. A sig-
niﬁcant increase in intracellular Grx activity of the 22 patients was seen. When analyzing
the subgroupsdepending on statin treatment (b) or diabetes subtype (c), therewasnodif-
ference in the PBMC response depending on statin treatment or diabetes type.
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When analyzing intracellular PBMC Grx1 activity, we found a signif-
icant increase after 12weeks of CoQ10 treatments (Table 2, Fig. 3a). Theincrease was similar in statin treated patients as well as in patients not
on statin treatment (Fig. 3b), and similar in type 1 and type 2DMpatient
groups (Fig. 3c). To conﬁrm the results, we analyzed Grx1 mRNA ex-
pression in the same PBMC samples, and in line with the increase in
Grx1 activity, there was also an increase in Grx1 mRNA expression
(Fig. 4), after 12 weeks of CoQ10 treatment.
3.4. Evidence for a GSH-dependent CoQ10 reduction, catalyzed by Grx1
The results from serum and intracellular Grx1 activity measure-
ments suggested that there may be a link between CoQ10 and Grx1, ei-
ther by CoQ10 being directly reduced by Grx1 or part of the reduction
process. We tested our hypothesis by incubating different concentra-
tions of CoQ10 with GSH (10 mM) in the presence of GR (10 nM),
NADPH (0.2 mM), with or without 20 μMGrx1. We found that GSH re-
duces CoQ10 quite comparable to TrxR, and that the reduction of CoQ10
is catalyzed by the addition of Grx1 (Fig. 5). We assume that 1 mol
NADP+ produced equals 1 mol CoQ10 reduced. Because of the turbidity
caused when adding more than 100 μM CoQ10, we were not able to
reach saturation of the reaction, thus a Lineweaver–Burk plot could
not be created andKmcould not be determined. To compare the catalyt-
ic efﬁciency of this novel mechanism, with the previously described
TrxR mediated CoQ10 reduction [28], we repeated the experiments of
Xia et al. [28]. In our experimental setup, we used 0.2 mM NADPH,
100 nM ﬁnal concentration TrxR, and 50 μM CoQ10. We assume that
1 mol NADP+ produced equals 1 mol CoQ10 reduced, as above. The re-
sult is 0.45 μM reduced CoQ10 per minute. Comparing the catalytic
19S.J. Montano et al. / BBA Clinical 4 (2015) 14–20activity, this equals a Kcat of 4.5 perminute per TrxRmolecule, whereas
the Kcat of Grx1 is 0.05 per minute per Grx1 molecule. This low Kcat of
Grx1 is however misleading, as it to a large extent may be explained by
the high background reducing activity of GSH. When comparing the
amount of reduced CoQ10 depending on CoQ10 concentration, the
GSH/Grx system is actually a slightly better reductant (Fig. 5).
4. Discussion
In the current study, we found that 12 weeks of oral CoQ10 treat-
ment decreased extracellular Grx1 activity and total antioxidant capac-
ity as well as fp-LDL, oxidized LDL cholesterol, and total cholesterol,
indicating an improvement towards a less oxidized extracellular envi-
ronment. The ﬁndings are in linewith our previous proposal that extra-
cellular Grx1 is a predictor of impaired extracellular redox balance and
impaired coping with hyperglycemia induced oxidative stress, thus a
risk marker for DM onset and progression [8], and the ﬁnding that in-
creased Grx1 attenuates post-ischemia revascularization in a mouse
model [9]. When analyzing statin treated and non-statin treated sub-
groups in the CoQ10 patients, the positive changes in redox parameters
and lipid status were only signiﬁcant in the non-statin treated popula-
tion. In our study, baseline CoQ10 levels were in the same range as pre-
viously described [12,29]. CoQ10 treatment increased serum CoQ10
levels signiﬁcantly in all patients. In fact, the increasewas slightly higher
than expected for 12 weeks CoQ10 treatment, even if other studies also
have described a threefold increase in CoQ10 levels [21]. Possibly, the
high levels were achieved due to the quite high levels of circulating p-
LDL in the patients, binding to CoQ10 and thus keeping high levels of
CoQ10 in the circulation. Serum CoQ10 levels increased regardless of
statin treatment and type of DM, thus, theremust be other factors deter-
mining that the positive antioxidant response only occurred in non-
statin treated patients.
In the current studywemeasured serumCoQ10 levels and not intra-
cellular levels, and as it is well known that serum CoQ10 levels do not
always reﬂect intracellular CoQ10 levels [30], we speculate that CoQ10
cellular uptake may be somehow perturbed in statin treated patients
rendering lower intracellular levels, which would explain the lack of
positive antioxidant effects in the statin treated patients. In support of
this, it has been shown that although shorter time statin treatment
does not alter the intracellular production of CoQ10 [31,32], long time
statin treatment does decrease CoQ10 serum levels [33]. In fact, statin
treatment has been reported to be amoderate risk factor for developing
type 2 diabetes [34].
Recently, two large clinical studies have been performed on the ef-
fects of CoQ10 supplementation. The ﬁrst was a population based pro-
spective, randomized double blind placebo controlled study of CoQ10
and selenium supplementation, showing a decreased mortality at
5 year follow-up [24], and the second was a randomized controlled
study of CoQ10 in chronic heart failure, where CoQ10 treatment im-
proved symptoms and reduced cardiovascular events [23]. Although
the majority of the patients did not have diabetes, a signiﬁcant propor-
tion of patients were on statin treatment. These studies show that high
serum CoQ10 levels (similar levels that we report in the current study)
are needed for a protective effect on cardiovascular events and mortal-
ity. This suggests that even if basal CoQ10 levels are increased by 50–
75% in diabetes compared to healthy controls, the endogenous levels
are too low to reduce oxidative stress. In our study, oxidized LDL, fp-
LDL and cholesterol levelswere signiﬁcantly reduced upon CoQ10 treat-
ment, and HbA1c levels tended to improve, thus indicating a possible
beneﬁcial effect also in clinical parameters, despite the small patient
size and relatively short treatment period.
Additionally, we describe for the ﬁrst time that Grx catalyzes the re-
duction of CoQ10 by GSH. As TrxR has previously been demonstrated to
reduce CoQ10 [28], we assessed this TrxR catalyzed CoQ10 reduction in
our experimental system and found Kcat similar to the Grx1 catalyzed
GSH reduction of CoQ10. These results show a new mechanism forin vivo CoQ10 reduction. Additionally, at physiological concentrations
(GSH 10 mM, Grx1 20 μM, and TrxR 0.1 μM) it may well be that GSH
and Grx1 are more important for reducing CoQ10 than TrxR.
In the present study, we found that as the extracellular Grx1 de-
creased by CoQ10 treatment, intracellular Grx1 levels as well as Grx1
mRNA increased. The reason behind the intracellular Grx increase is un-
clear and warrants further investigation, where the main intracellular
antioxidant glutathione (GSH), present at mM concentrations in the
cell and known to be decreased in type 2 diabetes compared to healthy
[35], should be assessed as well as the balance between its oxidized
(GSSG) and reduced (GSH) state, changes of which may affect intracel-
lular as well as extracellular Grx levels.
In conclusion,we have described thatmarkers of oxidative stress, in-
cluding extracellular Grx1 and oxidized LDL, are reduced upon treat-
ment of DM patients with CoQ10. Moreover, we have described a
novel mechanism for in vivo CoQ10 reduction via GSH, catalyzed by
Grx1. The positive effects of CoQ10 treatment on redox parameters as
well as on the lipid proﬁle and metabolic control may have clinical im-
plications in DM.
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